FOXP3 and chronic kidney disease: Notably, the expanded alloTregs from controls and CKD patients maintained >80% FOXP3+CD25+ (Figure S9D) and did not significantly reduce their FOXP3 expression levels in the absence of TGF-β and rapamycin (Figure S9E).